Εμφάνιση απλής εγγραφής

dc.creatorBogogiannidou Z., Speletas M., Vontas A., Nikoulis D.J., Dadouli K., Kyritsi M.A., Mouchtouri V.A., Mina P., Anagnostopoulos L., Koureas M., Karavasilis V., Nikou O., Pinaka O., Thomaidis P.C., Kadoglou K., Bedevis K., Spyrou N., Eleftheriou A.A., Papaevangelou V., Gikas A., Vatopoulos A., Ntzani E.E., Prezerakos P., Tsiodras S., Hadjichristodoulou C.en
dc.date.accessioned2023-01-31T07:38:51Z
dc.date.available2023-01-31T07:38:51Z
dc.date.issued2021
dc.identifier10.3390/vaccines9050504
dc.identifier.issn2076393X
dc.identifier.urihttp://hdl.handle.net/11615/71778
dc.description.abstractA serosurvey of IgG antibodies against SARS-CoV-2 was conducted in Greece between May and August 2020. It was designed as a cross-sectional survey and was repeated at monthly intervals. The leftover sampling methodology was used and a geographically stratified sampling plan was applied. Of 20,110 serum samples collected, 89 (0.44%) were found to be positive for anti-SARS-CoV-2 antibodies, with higher seroprevalence (0.35%) observed in May 2020. The highest seroprevalence was primarily observed in the “30–49” year age group. Females presented higher seroprevalence compared to males in May 2020 (females: 0.58% VS males: 0.10%). This difference reversed during the study period and males presented a higher proportion in August 2020 (females: 0.12% VS males: 0.58%). Differences in the rate of seropositivity between urban areas and the rest of the country were also observed during the study period. The four-month infection fatality rate (IFR) was estimated to be 0.47%, while the respective case fatality rate (CFR) was at 1.89%. Our findings confirm low seroprevalence of COVID-19 in Greece during the study period. The young adults are presented as the most affected age group. The loss of the cumulative effect of seropositivity in a proportion of previous SARS-CoV-2 infections was indicated. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.en
dc.language.isoenen
dc.sourceVaccinesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85106555308&doi=10.3390%2fvaccines9050504&partnerID=40&md5=69dd00ef429d29c3adc189f5318f6b12
dc.subjectimmunoglobulin G antibodyen
dc.subjectSARS-CoV-2 antibodyen
dc.subjectadulten
dc.subjectageden
dc.subjectArticleen
dc.subjectcase fatality rateen
dc.subjectchemiluminescent microparticle immunoassayen
dc.subjectchilden
dc.subjectcontrolled studyen
dc.subjectcoronavirus disease 2019en
dc.subjectcross-sectional studyen
dc.subjectfemaleen
dc.subjectgeographic distributionen
dc.subjectGreeceen
dc.subjecthumanen
dc.subjectimmune responseen
dc.subjectinfection fatality rateen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmortalityen
dc.subjectnonhumanen
dc.subjectsensitivity and specificityen
dc.subjectseroepidemiologyen
dc.subjectseroprevalenceen
dc.subjectSevere acute respiratory syndrome coronavirus 2en
dc.subjectMDPI AGen
dc.titleRepeated leftover serosurvey of sars-cov-2 igg antibodies in greece, may to august 2020en
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής